| 摘要: |
| 目的 探讨胰管支架置入在预防高危患者经内镜逆行胰胆管造影(ERCP)术后胰腺炎(PEP)及高淀粉酶血症中的作用。 方法 回顾性分析2013年1月至2014年12月间我院行ERCP治疗的160例PEP高危患者的临床资料。依据是否置入胰管支架,将其分为胰管支架组82例(放置支架)和对照组78例(未放置支架)。观察患者术后腹痛情况,监测术后3、24 h血清淀粉酶水平, 比较两组术后PEP、高淀粉酶血症的发生率。 结果 胰管支架组术后3 h和术后24 h血清淀粉酶水平分别为(184.89±257.33)U/L和(268.07±344.73)U/L,均低于对照组[分别为(305.35±371.81)U/L和(465.86±639.94)U/L],差异有统计学意义( P <0.05)。胰管支架组PEP、高淀粉酶血症发生率[2.4%(2/82)、17.1%(14/82)]低于对照组[11.5%(9/78)、30.8%(24/78)],差异有统计学意义( P <0.05)。胰管支架组术后腹痛发生率、腹痛评分[19.5% (16/82)、(1.24±0.58)]均低于对照组[43.6%(34/78)、(1.68±0.97)],差异有统计学意义( P =0.001)。 结论 胰管支架置入可有效预防高危患者PEP及高淀粉酶血症的发生。 |
| 关键词: 胰管支架 内镜逆行胰胆管造影术 胰腺炎 高淀粉酶血症 高危患者 |
| DOI：10.3724/SP.J.1008.2015.01319 |
| 投稿时间：2015-07-29修订日期：2015-09-06 |
| 基金项目: |
|
| Pancreatic duct stent preventing post endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients |
| WEI Lu*,LI Ping,WANG Chang-qing |
(Department of Gastroenterology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, Jiangsu, China
*Corresponding author.) |
| Abstract: |
| Objective To evaluate the preventive effect of pancreatic duct stent against post endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) and hyperamylasemia in high-risk patients. Methods A total of 160 patients with high-risk PEP underwent ERCP therapy between Jan. 2013 and Dec. 2014 and were retrospectively analyzed. The patients were divided into pancreatic duct stent group (n=82) and control group (n=78) according to whether receiving pancreatic duct stent or not. Abdominal pain was evaluated after ERCP. The levels of serum amylase were detected at 3 h and 24 h after ERCP. The incidences of PEP and hyperamylasemia were compared between the two groups. Results The serum amylase levels at 3 h and 24 h after ERCP in pancreatic duct stent group were significantly lower than those in control group ([184.89±257.33] U/L vs [305.35±371.81] U/L, P <0.05; [268.07±344.73] U/L vs [465.86±639.94] U/L, P <0.05). The incidences of PEP and hyperamylasemia in pancreatic duct stent group were also significantly lower than those in control group (2.4%[2/82] vs 11.5%[9/78], P <0.05;17.1%[14/82] vs 30.8%[24/78], P <0.05). The incidence of abdominal pain and abdominal pain score were (19.5%[16/82], [1.24±0.58]) in pancreatic duct stent group, which were significantly lower than those in control group (43.6% [34/78], [1.68±0.97]) ( P =0.001). Conclusion Pancreatic duct stent can effectively prevent PEP and hyperamylasemia in high-risk patients following ERCP. |
| Key words: pancreatic duct stent endoscopic retrograde cholangiopancreatography pancreatitis hyperamylasemia high-risk patients |
